Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Prior treatment

• Patients receiving any biological therapy currently or within 52 weeks prior to inclusion;
• The participation in any clinical study currently or within 52 weeks prior to inclusion;

Other illness

• Presence of chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (ILF) currently or in the anamnesis;
• An acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results.

• Age ≥ 18 years at the time of inclusion;
• Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;
• Patients with diagnosis of uncontrolled SA (Asthma Control Questionnaire-5 (ACQ-5) score \> 1,5) established no less than 52 weeks prior to inclusion; Severe asthma is defined as asthma, that is controlled due to treatment with ICS in medium or high doses plus LABA and/or ALP, and/or LAMA, and/or systemic corticosteroids (sCS), and/or immunobiological therapy, while attempts to reduce the volume of therapy lead to a loss of symptom control, or asthma remains uncontrolled despite this treatment. Such therapy should be carried out at least 3 months before inclusion.
  • Uncontrolled asthma is defined as ACQ-5\>1.5.
• Patients with the availability of at least 52 weeks of follow-up data (prior to inclusion) in the medical records.